Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis

Lowder, Careen Y.

doi:10.1001/archophthalmol.2010.339

Cited by 620 publications

(545 citation statements)

References 14 publications

Supporting

Mentioning

513

Contrasting

Unclassified

Order By: Relevance

“…93 The combination of both local and systemic delivery of targeted therapy will undoubtedly enhance the outcome for our patients, however, local steroid use is not without problems relating to ocular morbidity (cataracts, glaucoma, and endophthalmitis) as highlighted in the Retisert trial. 94 Nevertheless, there remains a consensus for the need to reduce patients' use of systemic steroids, and local administration, either singly or combined with non-steroid systemic immunosuppression, coupled with advances in drug delivery such as the recently FDA-approved intravitreal dexamethasone implant (Ozurdex), 95 have the potential, to facilitate control of intraocular inflammation.…”

Section: Recent and Future Treatmentsmentioning

confidence: 99%

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Lee

Dick

2011

Eye

View full text Add to dashboard Cite

The blockbuster drug paradigm is under increasing scrutiny across the biopharmaceutical industry. Intraocular inflammation poses particular challenges to this, given the heterogeneity of conditions in the uveitis spectrum, and the increasing acknowledgement of individual patient and disease variance in underlying immune responses. This need has triggered a drive towards personalised and stratified medicine, supported and enabled as a result of continued development of both experimental models and molecular biological techniques and improved clinical classification. As such we have the ability now to systematically appraise at a genomic, transcriptomic, and proteomic level individual immunophenotype, and the promise that in the eye this can be augmented by in vivo immune imaging to identify individual immunopathology. With such advances all running in parallel, we are entering an era of experimental medicine that will facilitate early diagnosis, generate biomarkers for accurate prognostication, and enable the development of individualised and targeted therapies, which can progress rapidly into clinical practice.

show abstract

Section: Recent and Future Treatmentsmentioning

confidence: 99%

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Lee

Dick

2011

Eye

View full text Add to dashboard Cite

show abstract

“…But as approval of dexamethasone (DEX) intravitreal implant for uveitis patients, recent clinical studies have demonstrated its safety as monotherapy for the treatment of non-infectious intermediate and posterior uveitis. 7,8 Its effectiveness in the treatment of uveitic ME in PPV eyes has also been reported with good results. 9 1 The purpose of this study was to compare the effectiveness of 0.7-mg DEX-intravitreal implant in noninfectious uveitic ME in eyes without previous PPV (non-PPV) vs eyes with previous PPV.…”

Section: Introductionmentioning

confidence: 96%

Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis

Pelegrín

Maza

Molins

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose To compare dexamethasone (DEX) intravitreal implant effect in nonvitrectomized (non-PPV) vs vitrectomized (PPV) eyes with macular edema (ME) secondary to non-infectious uveitis. Methods Medical records of patients with uveitic ME treated with DEX-intravitreal implant were reviewed. Main outcome measures were changes in central retinal thickness (CRT), best corrected visual acuity (BCVA), intraocular pressure (IOP), vitreous haze and adverse events. Statistical analysis was performed by Longitudinal Linear model using the General Estimating Equation methodology. Results Forty-two eyes of 32 patients were included. Median follow-up time was 18 months (interquartile range (IQR): 12-24). Median CRT showed its maximum decrease at the first month in non-PPV and PPV eyes without statistically significant differences between both groups (P = NS). Median Snellen BCVA, converted to logarithm (LogMAR), showed its maximum improvement at third month in both groups without statistically significant differences between them (P = NS). Median IOP was higher in non-PPV eyes than in PPV eyes from third (P = 0.025) to 12th month (P = 0.013). Vitreous haze score improved in both groups since first month and showed no differences (P = 0.706). Reinjection was performed in 45.2% of eyes at a median time of 5 months IQR: (5-6). Ocular hypertension (47.6%) was the most common adverse event.Conclusions DEX-intravitreal implant for uveitic ME has similar long-term safety profile and good response measured in terms of CRT decrease, BCVA, and vitreous haze improvement in both groups. Non-PPV eyes following DEX-intravitreal implant showed higher IOP increase than PPV eyes, showing the need for close IOP monitoring.

show abstract

“…2 An adult case series of acute lymphoblastic leukaemia (B and T types) has shown a central nervous system relapse rate of 7% in those achieving remission with a median survival of only 6 months. 3 The confirmation of relapsed leukaemia in this case dramatically altered the management and prognosis for this patient. Rather than proceeding to maintenance chemotherapy the patient was treated with further induction and consolidation chemotherapy, radiotherapy to the orbits, and ultimately allogeneic stem cell transplantation.…”

Section: Commentmentioning

confidence: 84%

“…3,4 It has been used offlabel to treat macular oedema in vitrectomised eyes of diabetics 5 and in the oil-filled eye of a patient with ankylosing spondylitis. 6 Its future use is expected to expand and its behaviour in different vitreous cavity environments remains under assessment.…”

Section: Commentmentioning

confidence: 99%

Spontaneous relocation of a trapped retrolenticular slow-release dexamethasone implant (Ozurdex) in a silicone oil-filled eye of a pseudophakic patient

Banerjee

Petrou

Zvobgo

et al. 2014

Eye

View full text Add to dashboard Cite

Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis

Cited by 620 publications

References 14 publications

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation

Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis

Spontaneous relocation of a trapped retrolenticular slow-release dexamethasone implant (Ozurdex) in a silicone oil-filled eye of a pseudophakic patient

Contact Info

Product

Resources

About